MPM BioImpact
MPM BioImpact is a Boston-based biotech investment firm managing over $3 billion AUM that creates and backs therapeutic companies across modalities, including circular RNA, radiopharmaceuticals, CNS, and immuno-oncology, generating revenue through fund management fees and carried interest.
- Company typePrivate
- Founded2010
- HeadquartersBoston, United States
- Headcount11–50
- GTM typeB2B
- OfferingServices
What MPM BioImpact does
MPM BioImpact is a Boston-based biotechnology investment firm operating as MPM BioImpact LLC, founded in 2010 and managing over $3 billion in assets under management across early-stage venture funds, private and public impact funds (including the Oncology Impact Fund / BioImpact Equities), and a public equities strategy. The firm is the successor vehicle to the MPM Capital platform and reports a 30+ year track record encompassing 60 FDA-approved drugs and more than 120 M&A and IPO events. Its stated model is company creation: identifying breakthrough science, recruiting entrepreneur-operators with deep domain expertise, providing capital and operating support, and converting scientific assets into independent therapeutic companies.
The firm builds and backs therapeutic companies across modalities, including circular RNA medicines (Orna Therapeutics, built from MIT research and acquired by Eli Lilly), alpha-emitting radiopharmaceuticals (Aktis Oncology, Nasdaq: AKTS), psychedelic-inspired CNS therapeutics (Reunion Neuroscience, with FDA Breakthrough Therapy Designation for RE104 in postpartum depression), TCR-mimetic antibody therapies (Crossbow Therapeutics), and bispecific T cell engagers for solid tumors (newly formed K2 Therapeutics). Revenue is generated through management fees on committed and invested AUM and through carried interest from portfolio exits; pricing terms of fund vehicles are not publicly disclosed. The customer base is institutional LPs in the funds and the portfolio companies receiving capital and operating support.
MPM is led by Chairman and Managing Partner Ansbert Gadicke, M.D., Managing Partner Christiana Bardon, M.D., M.B.A., CEO and Entrepreneur Partner Joseph Bolen, Ph.D., CMO and Entrepreneur Partner Frank Neumann, M.D., Ph.D., and General Partner Todd Foley, supported by a deep Entrepreneur Partner bench drawn from operating roles at companies such as Pfizer, AstraZeneca, Sanofi-Aventis, Takeda, Kite/Gilead, Verastem, bluebird bio, and Arena Pharmaceuticals. The firm's strategic posture in 2024–2026 has been one of expanded company formation, lead-investor roles in public and private financings (e.g., up to $306.9M DBV Technologies PIPE), inbound strategic capital from Meiji Seika Pharma, and high-profile exits, supported by continued investment team expansion.
MPM BioImpact firmographics
Firmographics- Name
- MPM BioImpact
- Legal name
- MPM BioImpact LLC
- Website
- https://mpmbioimpact.com
- Company type
- Private
- Founded year
- 2010
- Operating status
- Operating
- Headcount range
- 11–50 employees
- Short description
- MPM BioImpact is a Boston-based biotech investment firm managing over $3 billion AUM that creates and backs therapeutic companies across modalities, including circular RNA, radiopharmaceuticals, CNS, and immuno-oncology, generating revenue through fund management fees and carried interest.
- Ownership category
- akta.pro rank
MPM BioImpact industry classification
Industry- Product category
- Biotechnology Venture Capital Investment
- NAICS
- Open-End Investment Funds (525910), Research and Development in Biotechnology (except Nanobiotechnology) (541714)
- SIC
- Investment Advice (6282)
- akta.pro primary industry
- Impact Investing & Social Finance (Funds, CDFIs, Microfinance) (BPAGALAA)
Keywords
Where MPM BioImpact is headquartered
LocationHeadquarters
- HQ city
- Boston
- HQ country
- United States
- HQ region
- North America
Offices1 record
Markets served
MPM BioImpact business model
Business model- GTM type
- B2B
- Offering type
- Services
- Cost components
- Personnel, Operations, Technology or R&D, Marketing or Sales, Others
Revenue model
- Venture Capital Management: MPM BioImpact generates revenue through traditional venture capital mechanisms including management fees on funds under management and carried interest from successful portfolio company exits. They manage over $3 billion AUM across early-stage venture funds, private/public impact funds and a public equities fund.
Go-to-market motion1 record
Distribution channels1 record
Marketing channels4 records
MPM BioImpact product offering
Product offeringCore offering
MPM BioImpact is a biotechnology investment firm that builds and funds companies across all stages of drug development, managing over $3 billion in assets under management across early-stage venture funds, private/public impact funds, and a public equities fund. The firm identifies innovative science, recruits entrepreneur partners with deep domain expertise, and provides capital and operational support to transform scientific breakthroughs into life-saving medicines.
Product overview
MPM BioImpact is a biotechnology investment firm that creates and invests in innovative companies seeking to deliver transformative therapies to patients. Rather than offering traditional software products, the firm provides investment management, company building, and funding services across all stages of drug development. The firm manages over $3 billion AUM across early-stage venture funds, private/public impact funds, and a public equities fund. Their BIOIMPACT FUND investment approach invests in companies which aim to transform patient outcomes. The firm has built multiple biotech companies including Orna Therapeutics (circular RNA medicines), Aktis Oncology (alpha radiopharmaceuticals), Reunion Neuroscience (mental health disorders), and Crossbow Therapeutics (TCR-mimetic antibody therapies).
Differentiator
Problem solved
Functional benefit
Products and services
- Early-Stage Venture Funds Equity investment funds that provide capital to early-stage biotechnology companies, supporting company creation and operational development to transform scientific breakthroughs into medicines.
- BIOIMPACT Fund (Private/Public Impact Fund) Combined private and public equity fund strategy investing in companies aiming to transform patient outcomes, registered under the BIOIMPACT and BIOIMPACT EQUITIES trademarks. Signatory to the Operating Principles for Impact Management (OPIM).
- Oncology Impact Fund (OIF) Oncology-focused impact investment fund within the MPM BioImpact portfolio, targeting cancer therapeutics development.
- Public Equities Fund Public equities fund providing investment exposure to publicly-traded biotechnology companies, drawing on 10+ years of public investing experience at BioImpact.
Companies that use MPM BioImpact
Customer profileSegments2 records
Ideal customer profiles1 record
MPM BioImpact technology and API
TechnologyTechnology focussed No
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
MPM BioImpact partnerships and signals
Strategic signalPartnerships
Three partnerships are on record, tiered core and minor.
- K2 TherapeuticscoreK2 Therapeutics was established by MPM BioImpact as a newly founded company. It obtained exclusive global rights (outside Greater China) from Antengene for ATG-106, a preclinical CDH6 x CD3 bispecific T cell engager for solid tumors, along with an option for an undisclosed preclinical bispecific TCE candidate.
- Global Standards / OPIMminorMPM BioImpact is a signatory to the Operating Principles for Impact Management (OPIM), demonstrating commitment to impact investment standards and transparency.
- BlueMarkminorMPM BioImpact engaged BlueMark to independently verify their impact management practices against industry best practices.
Scale indicators4 records
Recent moves8 records
Expansion highlights6 records
MPM BioImpact competitors and assessment
Company assessmentDirect peers
- RA Capital Management: RA Capital Management is a Boston-based crossover fund investing across public and private biotech with a focus on clinical and translational diligence. Its combined public/private biotech mandate and Boston presence directly mirror MPM BioImpact's BioImpact Equities and venture strategy.
- OrbiMed Advisors: OrbiMed is a healthcare-dedicated investment firm across venture, growth, public equity, and royalty/private credit strategies, with multi-billion AUM. Like MPM BioImpact, it invests across all stages of biotech development and combines private and public investment approaches.
- Third Rock Ventures: Third Rock Ventures is a Boston-based healthcare venture firm that builds biotech companies from scratch by assembling scientific founders, executive teams, and capital around breakthrough science. Its company-creation model and Boston biotech focus closely parallel MPM BioImpact's approach.
- Atlas Venture: Atlas Venture is a Boston-based early-stage biotech venture capital firm that builds and funds therapeutics companies from inception through clinical proof-of-concept. Its operating model of company creation and seed/Series A focus on platform and modality biotech is highly comparable to MPM BioImpact.
- Flagship Pioneering: Flagship Pioneering is a Boston-based biotechnology company creation and venture capital firm that builds and funds biotech companies from inception. Like MPM BioImpact, it combines company-building expertise with deep scientific networks to originate and grow transformational therapeutics platforms.
- SV Health Investors: SV Health Investors is a healthcare and biotechnology venture and growth equity firm with multiple dedicated biotech funds. Its stage-diversified biotech mandate and focus on transformative therapeutics align closely with MPM BioImpact's investment approach.
- Baker Bros. Advisors: Baker Bros. Advisors is a biotech-focused investment adviser managing long-only public equity and private venture funds. Its dedicated biotech focus across private and public markets makes it a strong comparable to MPM BioImpact's multi-strategy biotech mandate.
- ARCH Venture Partners: ARCH Venture Partners is a long-established early-stage technology and life sciences venture firm known for founding breakthrough biotech companies. Its deep-science, company-creation orientation and multi-billion AUM make it a direct comparable to MPM BioImpact.
- Sofinnova Investments: Sofinnova Investments is a life sciences-focused venture firm investing from seed through late-stage clinical across therapeutics and platforms. Its exclusive biotech focus and stage-diversified approach make it a direct comparable to MPM BioImpact.
- 5AM Ventures: 5AM Ventures is an early-stage venture firm focused on building next-generation biotech companies in platforms and therapeutics. Its company-creation approach in life sciences makes it a direct comparable to MPM BioImpact's venture strategy.
Market position
Strengths5 records
Weaknesses5 records
Competitive moat5 records
Key risks5 records
Key highlights7 records
Customer concentration
MPM BioImpact social profiles
Digital presenceMPM BioImpact financial estimates
Financial estimateRevenue estimate
Valuation estimate
MPM BioImpact leadership team
Management profileNumber of profiles
Profiles12 records
MPM BioImpact subsidiaries and ownership
Company hierarchySubsidiaries1 record
MPM BioImpact funding detail
Funding detailFunding overview
Funding rounds1 record
Investors1 record
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
MPM BioImpact M&A and investment
M&A and investmentM&A
Investments6 records
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about MPM BioImpact
What does MPM BioImpact do?
MPM BioImpact is a biotechnology investment firm that builds and funds companies across all stages of drug development, managing over $3 billion in assets under management across early-stage venture funds, private/public impact funds, and a public equities fund. The firm identifies innovative science, recruits entrepreneur partners with deep domain expertise, and provides capital and operational support to transform scientific breakthroughs into life-saving medicines.
Is MPM BioImpact a public or private company?
MPM BioImpact is a private company. It is classified as venture growth investor backed and is currently operating.
When was MPM BioImpact founded?
MPM BioImpact was founded in 2010. It employs 11 to 50 people.
Where is MPM BioImpact based?
MPM BioImpact is headquartered in Boston, United States, in the North America region.
How does MPM BioImpact make money?
One revenue line is on record: venture Capital Management.
Who are MPM BioImpact's main competitors?
Direct peers on record are RA Capital Management, OrbiMed Advisors, Third Rock Ventures, Atlas Venture, Flagship Pioneering, SV Health Investors, Baker Bros. Advisors, ARCH Venture Partners, Sofinnova Investments and 5AM Ventures.
Does MPM BioImpact have an API?
No public API is recorded for MPM BioImpact.
What industry is MPM BioImpact in?
MPM BioImpact's product category is Biotechnology Venture Capital Investment. Its primary akta.pro industry code is BPAGALAA, Impact Investing & Social Finance (Funds, CDFIs, Microfinance). Its NAICS code is 525910 and its SIC code is 6282.